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Why was the cohort set up?
The effects of exposure to ionizing radiation have been studied for decades. The health 
effects of moderate to high exposure are well characterized, but the effects of low-level, 
chronic exposure remain a subject of continued debate.1 Moreover, repeated or protracted 
low-dose rate exposures to ionizing radiation have become increasingly common over the 
past quarter-century.1 The largest contributor to this trend has been medical radiation expos-
ure.2,3 Since the 1980s, studies of nuclear industry workers have been conducted to provide 
direct information about these effects.2,3 These cohorts are well suited for this purpose: they 
include large number of workers, with individual (person-specific) monitoring of external 
doses and many years of follow-up. Estimates from early, cohort-specific studies, were, 
however, compatible with a wide range of possibilities, from a reduction of risk at low doses 
to risks higher than those on which current radiation protection recommendations are based.
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To further improve the precision of estimates of radiation-induced cancer risk following 
protracted low doses of ionizing radiation and to strengthen the scientific basis of radiation 
protection standards, an International Collaborative Study of Cancer Risk among Radiation 
Workers in the Nuclear Industry, the ‘15-Country Study’, was carried out using a common 
core protocol in 15 coun-tries.3–5 Information was collected on nearly 600000 workers and a 
thorough study of errors in recorded doses was carried out to evaluate the comparability of 
recorded dose estimates across facilities and time, and to identify and quantify sources of 
bias and uncertainties in dose estimates, which were taken into account in the statistical 
analyses of the results.6
Within the 15-country study, the cohorts of nuclear workers from France, the UK and the 
USA provided the vast majority of the information available on early nuclear workers. They 
provided 62% of the person-years of follow-up and 67% of cancer and leukaemia deaths. In 
recent years, the cohorts from France, the UK and the USA have been updated.
The International Nuclear Workers Study (INWORKS) was therefore established to provide 
a basis for deriving more precise quantitative estimates of the risk of chronic, low-level 
exposure to ionizing radiation, through an improved understanding of the association 
between protracted low-dose exposure to ionizing radiation and mortality due to solid and 
haematological cancers, and circulatory diseases. Specifically, the INWORKS consortium 
builds upon the work conducted for the 15-country study by taking advantage of data from 
the most informative cohorts involved in that study. INWORKS has the potential to improve 
on estimates obtained from the 15-country study and the knowledge derived from the 
information on workers exposed to chronic, low-dose exposures will contribute to the 
understanding of risks to members of the public exposed to background (low-level, chronic) 
radiation. INWORKS is organized by, and data are housed at, the International Agency for 
Research on Cancer (IARC).
Who is in the cohort?
INWORKS is a retrospective cohort study of workers employed by: the Atomic Energy 
Commission (CEA), AREVANuclear Cycle (formerly COGEMA) and the National 
Electricity Company (EDF) in France; the Departments of Energy and Defense in the USA; 
and, in the UK, by nuclear industry employers included in the National Registry for 
Radiation Workers (NRRW). Table 1 lists the facilities and companies represented in the 
study countries. Inclusion criteria are based on completeness and quality of data, start of 
facility operations and other considerations; details of the country-specific inclusion criteria 
can be found elsewhere.7–10 Workers who were employed in the nuclear industry for less 
than 1 year were excluded from INWORKS. In France, workers were given the opportunity, 
required by the French Data Protection Authority, to refuse participation; however, none 
refused to participate. In the USA, worker information is based on existing records, with no 
effort made to directly contact any participants; because there is minimal risk to participants, 
the National Institute for Occupational Safety and Health Institute Review Board (NIOSH 
IRB) waived requirements for informed consent. Finally, UK workers have the opportunity 
to refuse to participate in the NRRW and associated studies; less than 1% of UK radiation 
workers refused to participate.
Hamra et al. Page 2
Int J Epidemiol. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Table 2 summarizes the number of workers included in INWORKS by country and by some 
key characteristics. Approximately 20% of the US workers are women. In contrast, the UK 
and French cohorts include approximately 9% and 13% female workers, respectively. The 
mean year of birth for the USA cohort is 1934, and the mean years of birth for French and 
UK cohort members are 1947 and 1944, respectively; this reflects the differing employment 
dates of the different cohorts. The average age at the start of employment is similar for 
workers from each country, ranging from age 27 to 30 years. The mean age at the end of 
follow-up for the USA cohort members is, on average, nearly a decade greater than for the 
UK and French cohorts. In total these workers contributed 8.2 million person-years of 
observation to the study. A summary of the person-time and number of mortality events 
experienced by each cohort grouped by categories of age, birth cohort, socioeconomic status 
and sex can be found in the eSupplement (available as Supplementary data at IJE online).
Table 3 reports the distribution of individuals in categories of cumulative dose, average 
annual dose, average cumulative dose and total measured whole-body dose by country and 
for the pooled cohort. Workers in the USA and UK cohorts received higher ionizing 
radiation doses than the workers in the French cohort, both in terms of average annual dose 
and average cumulative dose.
The number of deaths in INWORKS is 66632. The total number of deaths from cancer and 
circulatory disease is summarized in Table 4 by subtype. International Classification of 
Disease codes used to group outcomes can be found in the eSupplement (available as 
Supplementary data at IJE online). Cancer and circulatory disease rates increase with age, 
and therefore the number of deaths due to these causes has approximately tripled since the 
last time that the French, USA and UK cohorts were analysed together with a reported 
19748 deaths due to solid and haematological cancers and 27 848 deaths due to circulatory 
disease (Table 4).
Longer follow-up allows for better estimation of temporal factors affecting the relationship 
between low-level ionizing radiation and mortality; and the large number of observed events 
allows more effective consideration of the association of mortality risk of specific solid and 
haematological cancers and exposure to ionizing radiation.
How often has the cohort been followed up?
In France, follow-up commenced in 1968 because the French national death registry has 
only recorded information on individual causes of death since 1968; follow-up is updated 
biannually with cause of death obtained from the French National Institute for Medical 
Research.11 In the UK, follow-up commences from 1955 with updates of mortality 
information obtained on an ongoing basis from central registries for England, Wales and 
Scotland, as well as at intervals from regional offices for workers resident in the Channel 
Islands, the Isle of Man or Northern Ireland.9,10 In the USA, follow-up commenced with 
start of operations at each facility (1944 for the earliest nuclear facility in the USA), and 
cause of death is obtained from the National Death Index (from 1979 onwards, and from US 
State and multiple other sources before that year). The cause of death is confirmed through 
periodic searches of social security administration records conducted by the US National 
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Institute for Occupational Safety and Health.7 Because information is obtained from 
employers and national registries, loss to follow-up is minimal: only 0.22%, 2.56% and 
0.83% of employees were lost to follow-up or emigrated from the French, UK and US 
cohorts, respectively (Table 2).
What has been measured?
Information on demographic variables, including sex and date of birth, as well as race for 
US workers, was obtained from employment records. Information on periods of radiation 
work, job titles and facilities of employment, and a classification of workers according to 
socioeconomic status was collected as well. Information regarding date and cause of death is 
collected (and periodically updated) by linkage to population registries in each country. 
Because of the nature of the study, information regarding individual health-related 
behaviours could not be collected. Because a large percentage of the cohort is now deceased, 
and because of the large number of workers, it would not be feasible to collect this 
information for the current consortium.
Workers from the nuclear industry represent a unique population to study the health effects 
of ionizing radiation; they are mostly exposed to radiation at low levels over the course of 
their working life. Moreover, unlike typical occupational cohort studies, all workers included 
in INWORKS have records that provide individual quantitative radiation dose estimates. 
Workers in INWORKS were mainly exposed to external radiation, usually gamma-rays, and 
doses were measured regularly with personal dosimeters. For all participating cohorts, 
records of individual recorded doses have been kept since the very beginning of the industry 
in the 1940s.
The main sources of errors in recorded external doses were quantified in order to account for 
the evolution of technology since the beginning of the nuclear industry and for differences in 
practices between facilities or countries.6 Correction factors were derived by dosimeter type 
to account for bias and associated uncertainties and recorded doses were converted into 
organ doses.6 The International Commission for Radiological Protection (ICRP) provides 
conversion coefficients to obtain estimates of organ-specific doses from external radiation 
exposure. Previous studies utilized these estimates from ICRP-5112 and ICRP-7413 reports. 
Recently, these estimates have been updated by the ICRP,14 allowing separate organ dose 
estimation for men and women. This is important for diseases that are highly sex specific; 
for example, the revised coefficients allow a sex-specific estimation of dose to the breast for 
women. The revised coefficients have therefore been used in the INWORKS analyses.
What has been found? Key findings and publications
A summary of the published results regarding the participating cohorts and previous 15-
country study is provided in Table 5; we also provide a brief summary of some of the more 
recent analyses undertaken within each country. Country-specific studies, as well as the 
previous 15-country study, find a positive relationship between mortality from solid cancer 
and leukaemia excluding chronic lymphocytic leukaemia (CLL) and occupational exposure 
to ionizing radiation with varying levels of magnitude and precision. Estimates for the 
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excess relative risk for solid cancers associated with 1 Sv increase in external radiation 
exposure in the French, UK and US cohorts were 0.34 [90% confidence interval (CI): −0.56, 
1.38,8 0.28 (90% CI: 0.02, 0.56)10 and 0.14 (95% CI: −0.17, 0.48),7 respectively. The excess 
relative risk for solid cancer estimated in the 15-country study was 0.87 (95% CI: 0.03, 
1.88).3
All the previous studies, individual and pooled, find a positive relationship between 
mortality from leukaemia excluding CLL and occupational exposure to ionizing radiation 
with varying levels of magnitude; 3–5,7–9,11 generally, these estimates are statistically 
imprecise due to a low number of observed events. The excess relative risk estimates for 
leukaemia excluding CLL from French, UK, and US cohorts are: 3.96 (90% CI: < 0.0, 
16.82),11 1.71 (90% CI: 0.06, 4.29)9 and 1.7 (95% CI: −0.22, 4.7),7 respectively. In the 15-
country study, the risk estimate was 1.93 (95% CI: < 0.00, 8.47). In contrast, estimates from 
the Life Span Study (LSS) study of atomic bomb survivors, restricted to males ages 20 to 60, 
is 2.63 (90% CI: 1.50, 4.27).
To date, the key findings from INWORKS involve analyses of associations between 
radiation and leukaemia and lymphoma.15 Notably, the excess relative rate of mortality due 
to leukaemia excluding CLL was 2.96 (90% CI: 1.17, 5.21) per Gy estimated red bone 
marrow dose. Figure 1 provides a visualization of the change in the relative risk of 
leukaemia per unit increase in red bone marrow radiation dose. The estimated association 
between radiation dose and leukaemia excluding CLL, obtained from analysis of 
INWORKS, is substantially more precise than prior analyses of any specific cohort, larger 
than (and more precise than) the estimated association from the 15-country study and similar 
in magnitude and precision to the estimate from the LSS. Similarly to the previous analyses 
of the 15-country study data and the LSS, associations between radiation dose and 
leukaemia were based on estimated red bone marrow dose. In contrast, previous country-
specific analyses were based on recorded whole-body dose estimates. The results represent a 
major finding from occupational cohort mortality studies involving personal quantitative 
estimates of dose derived from individual monitoring over decades of employment for 
exposure to an occupational carcinogen. These findings provide a stronger empirical basis 
for protection from protracted or repeated low-dose radiation exposure.
What are the main strengths and weaknesses of this study?
As can be seen in Tables 2–4, the INWORKS study, by including a substantial number of 
additional years of follow-up (9 in the NRRW and the Idaho National Laboratory, 10 in 
France, 19 at Hanford and 21 at the Oak Ridge National Laboratory), has considerably 
increased the statistical power and information that can be drawn about the effects of low-
level chronic exposure to ionizing radiation compared with previous international studies. 
Further, workers who had potential for internal radiation dose and were excluded from the 
15-country study are included in INWORKS. When compared with the 15-country study, the 
average length of follow-up has gone from 12.75 to 26.67 years; the number of cancer 
deaths has multiplied by 3.75 and the number of leukaemia deaths by 2.5. These increases 
will not only improve the statistical precision of direct estimates of risk following low-dose 
protracted radiation exposure, but also allow the investigation of risk from a number of 
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different subtypes of cancer and specific non-cancer diseases and the investigation of the 
effect of age and time since exposure on risk of radiation-induced mortality. The 
international cohort is still young, however, with an average age of 58, an age at which the 
incidence of many cancer and non-cancer diseases is increasing. Further follow-up of this 
international cohort, in which much effort has been invested over the years to better 
characterize exposure, is thus likely to increase our understanding of radiation risk following 
low-dose protracted exposures in the next decades. Further, recent advances in classification 
of disease and in dosimetry (permitting more pertinent conversion factors to estimate doses 
to specific organs using the originally recorded dosi-metric quantities) allow now, and in the 
future, for the better quantification of risks associated with ionizing radiation. This better 
quantification of risk following low protracted exposure will also assist in understanding and 
explaining risk to the general population with exposures to either natural background or 
nuclear emissions at chronic low levels.
As with any pooling of cohorts there are, however, a number of limitations. Due to the size 
of the pooled cohort and the study design, it was not logistically feasible to obtain 
information on potential confounders (including smoking or other occupational exposures) 
for all cohort members. As with previous studies of radiation workers, it will be important to 
consider the patterns of exposure—in the main, nuclear workers accruing occupational 
exposure at low levels and over a long time. Further, occupational cohort studies are 
typically susceptible to a healthy worker hire effect, which has historically concerned the 
selection of workers into a cohort who are healthier than the general population and which 
therefore requires that care is taken in the interpretation of results.16 In terms of estimating 
radiation risks, an important limitation is the fact that we are unable to separately estimate 
the neutron component in radiation risk estimation. Measuring neutron exposure has been a 
challenging task, since the energy of neutrons could range from less than 1 electron volt 
(eV) to around 20 MeV and detectors were not able to measure all energies for relatively 
long periods of time.17 It is impossible to ensure that neutron exposure would have been 
correctly estimated for all workers in our international cohort. Some individuals might have 
had unrecorded or poorly estimated neutron doses. For some facilities and time periods, it 
was also impossible to separately estimate the neutron component of the external radiation 
dose. Because of this, and in order for our estimates of risk in relation to external radiation 
doses to be as accurate as possible, we have regrouped workers into categories of potential 
for neutron exposures.
Can I get hold of the data? Where can I find out more?
This study’s data are not freely available. For reasons of ethics and permissions from 
different agencies, the data are maintained at the International Agency for Research on 
Cancer (Lyon, France); further, it is not possible to send the data outside the agency. 
Proposals for possible collaborations in further analyses of the data should be addressed to 
Dr AusreleKesminiene [KesminieneA@iarc.fr] and will be reviewed by the INWORKS 
consortium.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Inworks in a Nutshell
• The INWORKS consortium was established to combine informative 
cohorts of nuclear workers from France, the UK and the USA, to study 
the association between cancer and non-cancer diseases and radiation 
exposure.
• A total of 308 297 workers provided 8.2 million person-years of 
follow-up from 1944 to 2005.
• The primary exposure of interest is external exposure to photon 
radiation. Records were obtained from selected employers and from 
employment elsewhere to estimate career radiation doses for each 
worker.
• Proposals for possible collaborations in further analyses of the data 
should be addressed to Dr Ausrele Kesminiene [KesminieneA@iarc.fr] 
and will be reviewed by the INWORKS consortium.
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Figure 1. 
Relative risk of leukaemia, except chronic lymphocytic leukaemia, associated with dose to 
red bone marrow among nuclear workers. Nuclear Workers in France, the UK and the USA, 
1943–2005 (Leuraud et al., in revision). The solid line is the fitted linear dose-response 
model (excess relative risk per Gy=2.96) and the dotted lines are the likelihood-based, linear 
fitted 90% CI. Bars represent 90% CI for relative risks. The diamonds represent the 
estimated relative risk at the level of exposure on the x-axis.
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Table 1
Nuclear facilities included in the INWORKS cohort, 1943–2005
County Facilities/companies included
France Atomic Energy Commission (CEA)
AREVA Nuclear Cycle (formerly General Company of Nuclear Fuel COGEMA)
National Electricity Company (EDF)
USA Hanford Site (Richland, WA)
Savannah River Site (SRS, Aiken, SC)
Oak Ridge National Laboratory (ORNL, Oak Ridge, TN)
Idaho National Laboratory (INL, Idaho Falls, ID)
Portsmouth Naval Shipyard (PNS, Kittery, ME)
UK Atomic Weapons Establishment
British Energy Generation and Magnox Electric Ltd
British Nuclear Fuels plc
Ministry of Defence
UK Atomic Energy Authority
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Table 4
Number of deaths in INWORKS by category of underlying cause of death, 1943–2005
Cause of death
Cohort
France UK USA Total
All solid cancers 2356 6994 8607 17957
 Bladder 56 273 250 579
 Brain 84 227 283 594
 Breast 75 75 260 410
 Colon / small intestine 172 542 856 1570
 Connective tissue 8 32 61 101
 Oesophagus 92 329 226 647
 Kidney 70 174 247 491
 Larynx 57 63 65 185
 Liver/gallbladder/ biliary 132 115 206 453
 Lung/trachea/bronchus 595 2244 2963 5802
 Ovary 21 22 79 122
 Pancreas 139 325 512 976
 Peritoneum 47 67 31 145
 Prostate 149 630 906 1685
 Rectum 61 313 165 539
 Stomach 99 542 263 904
 Thyroid 6 16 16 38
 Other solid cancers 493 1005 1218 2716
All haematopoietic and lymphoid cancers 196 564 1031 1791
 Hodgkin disease 17 33 54 104
 Non-Hodgkin lymphoma 64 227 419 710
 All leukaemia 79 208 397 684
 CLL 19 41 78 138
 Leukaemia excluding CLL 56 167 311 531
 Chronic myeloid leukaemia 14 39 47 100
 Multiple myeloma 36 96 161 293
Circulatory diseases 1483 11687 14678 27848
 Hypertension 39 165 380 584
 Ischaemic heart disease 587 7904 8972 17463
 Other heart diseases 357 717 2324 3398
 Cerebrovascular 338 2047 2059 4444
 Other cardiovascular diseases 162 854 943 1959
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Table 5
Results from recent analyses of the member countries of the INWORKS consortium, 1943–2005
Country Cohorts included Mortality ERR per Sv (90% CI)
UK full NRRW9 All malignant cancer excluding leukemia
Leukaemia excluding CLLa
Circulatory disease
Ischaemic heart disease
Cerebrovascular disease
  0.28 (0.02, 0.56)
  1.71 (0.06, 4.29)
  0.25 (0.03, 0.49)
  0.26 (0.00, 0.55)
  0.16 (−0.34, 0.77)
France AREVA NC, EDF, COGEMA8,11 Solid cancer
Leukaemia excluding CLLa
Circulatory disease
Ischaemic heart disease
Cerebrovascular disease
  0.34 (−0.56,1.38)
  3.96 (<0, 16.82)
  0.31 (−0.90,1.74)
  0.71 (−1.20, 3.18)
  0.99 (< 0.00, 5.05)
USA Hanford, SRS, ORNL, INL, PNS7 Solid cancerb
Leukaemia excluding CLLb
Cardiovascular diseaseb
  0.14 (−0.17, 0.48)
  1.7 (−0.22, 4.7)
  0.026 (−0.25, 0.32)
15-Country Study3–5 Solid cancerb
Leukaemia excluding CLLa
Circulatory diseaseb
Ischaemic heart diseaseb
Cerebrovascular diseaseb
  0.87 (0.03, 1.88)
  1.93 (<0, 8.47)
  0.09 (−0.43, 0.70)
−0.01 (−0.59 0.69)
  0.88 (−0.67, 3.16)
INWORKS15 Leukaemia excluding CLLa   2.96 (1.17, 5.21)
ERR, excess relative risk; CLL, chronic lymphocytic leukaemia; CI, confidence interval;<0 indicates that the lower bound of the confidence 
interval could not be calculated.
a
Indicates 2-year lag. Otherwise, a 10-year exposure lag is used.
b
Indicates 95% confidence interval rather than 90%.
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